Immunovant posts $153M net loss as R&D spending climbs in fiscal Q1
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/14/2026
- Nasdaq drags on Wall St as AI slowdown fears hammer Nvidia, chipmakers
- Global AI stocks fall as industry chiefs call for slowing development
- Trump slams Anthropic CEO over AI slowdown call
- Oil prices soar over 4% to 16-week high after Saudi strikes
- BofA sees just 2% upside for the S&P 500 over the next 12 months
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
August 6, 2026 9:56 AM EDTAll IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat rheumatoid arthritis (D2T RA), Sjögrens disease (SjD) and cutaneous lupus erythematosus (CLE)
Current cash balance provides runway to the potential launch of IMVT-1402 in GD
Roivant will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026
DURHAM, N.C., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal... More
